Sanofi-aventis announced today that results from two studies, GINGER
and LACE, presented at the 44th annual meeting of the European Association
for the Study of Diabetes (EASD) demonstrated that a basal-bolus insulin
regimen with LANTUS(R) (insulin glargine (rDNA origin) injection) once
daily (basal insulin) and rapid-acting APIDRA(R) (insulin glulisine [rDNA
origin] injection) at mealtime (bolus insulin) produced greater A1C
reductions versus pre-mixed insulin in people with type 2 diabetes. Both
studies, GINGER (a clinical trial) and LACE (real life patient data)
confirmed the superior efficacy of LANTUS(R)/APIDRA(R) basal-bolus therapy
when compared to pre-mixed insulin regimens.

Basal-bolus insulin regimens that combine once-daily LANTUS(R) as a
basal insulin with rapid-acting APIDRA(R) at mealtime closely mimic normal
physiologic insulin secretion that occurs in people without diabetes.

Patients with type 2 diabetes at two U.S. endocrinology practice
centers were randomized to LANTUS(R) and APIDRA(R) (n=106) or analog
pre-mixed insulin (n=91). Subsequent to randomization, patients continued
treatment following each center's usual practice with no additional
therapeutic protocols. Data collected with variations at 0, 3, 6 and 9
months included A1C, hypoglycemia, insulin dose, concomitant medications,
and therapy change. Medication costs were estimated using published average
wholesale price. Time variations between visits were accounted for in the
analysis of A1C.

Treatment groups were comparable at baseline with mean age 56 years,
46% male, 59% Caucasian, and 38% African-American, duration of diabetes 13
years, A1C 9.25%, and BMI 35.8 kg/m2. During the 4 months before
randomization, 88% used insulin with a mean daily dose of 71IU, about 70%
of patients used oral hypoglycemic agent(s) and 29% had chart records for
hypoglycemia. Mean follow-up time was 179 days. One patient (1%) randomized
to the LANTUS(R)/APIDRA(R) treatment therapy switched to the pre-mixed
insulin therapy, relative to 9 (10%) randomized to pre-mixed switched to
the LANTUS(R)/APIDRA(R) treatment therapy.

Sanofi-aventis, a leading global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New
York (NYSE : SNY).

(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...

(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...

(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...